Allogene Therapeutics (ALLO) Coverage Initiated at Cowen

Cowen assumed coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a report issued on Monday, MarketBeat reports. The brokerage issued an outperform rating on the stock.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. began coverage on Allogene Therapeutics in a research note on Monday. They set a neutral rating and a $29.00 price target for the company. Jefferies Financial Group began coverage on Allogene Therapeutics in a research note on Monday. They set a buy rating and a $31.00 price target for the company. Finally, Goldman Sachs Group began coverage on Allogene Therapeutics in a research note on Monday. They set a buy rating and a $41.00 price target for the company.

Shares of Allogene Therapeutics stock opened at $33.24 on Monday. Allogene Therapeutics has a 12 month low of $21.67 and a 12 month high of $35.55.

In related news, insider David D. Chang acquired 40,000 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $720,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arie Belldegrun acquired 35,000 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were bought at an average price of $18.00 per share, for a total transaction of $630,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 750,000 shares of company stock worth $13,500,000.

Read More: Earnings Per Share (EPS) Explained

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply